Changeflow GovPing Pharma & Drug Safety Biomarker Combinations for NASH and Hepatic Fib...
Routine Rule Added Final

Biomarker Combinations for NASH and Hepatic Fibrosis Diagnosis

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12601747B2 to Bio-Rad Laboratories for biomarker combinations used to diagnose Non-Alcoholic Steatohepatitis (NASH) and hepatic fibrosis status. The patent covers methods and kits for evaluating liver conditions based on three or more biomarker levels in subjects with NAFLD or NASH.

What changed

USPTO granted patent US12601747B2 to Bio-Rad Laboratories covering methods and kits for diagnosing NASH and hepatic fibrosis based on three or more specific biomarkers. The patent, with 5 claims, lists inventors including Isabelle Batxelli-Molina, Florian Salipante, Roger P. Walker, John Flanagan, and Jeannette Fareh-Michiel.

Affected parties including diagnostic laboratories, healthcare providers, and medical device manufacturers should monitor for potential licensing requirements or patent clearance needs when developing or using similar biomarker-based diagnostic methods for liver diseases.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status

Grant US12601747B2 Kind: B2 Apr 14, 2026

Assignee

BIO-RAD LABORATORIES, INC.

Inventors

Isabelle Batxelli-Molina, Florian Salipante, Roger P. Walker, John Flanagan, Jeannette Fareh-Michiel

Abstract

The invention provides a method of diagnosing Non-Alcoholic Steatohepatitis (NASH) and/or the hepatic fibrosis status of a subject, especially a subject afflicted with Non-alcoholic fatty liver disease (NAFLD) or NASH, based on the level of only three or more particular biomarkers. The invention further provides a kit suitable for performing said method and the use of said method and methods of treating patients diagnosed in accordance with the disclosed methods.

CPC Classifications

C07K 16/24

Filing Date

2023-11-06

Application No.

18502243

Claims

5

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12601747B2

Who this affects

Applies to
Medical device makers Healthcare providers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Patent grant Diagnostic testing Biomarker analysis
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!